IDEXX Laboratories, Inc. $IDXX is Railway Pension Investments Ltd’s 8th Largest Position

Railway Pension Investments Ltd raised its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 10.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 326,080 shares of the company’s stock after buying an additional 29,550 shares during the quarter. IDEXX Laboratories comprises 2.6% of Railway Pension Investments Ltd’s holdings, making the stock its 8th largest position. Railway Pension Investments Ltd’s holdings in IDEXX Laboratories were worth $220,603,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in IDXX. Empowered Funds LLC raised its stake in IDEXX Laboratories by 6.6% in the first quarter. Empowered Funds LLC now owns 1,538 shares of the company’s stock valued at $646,000 after buying an additional 95 shares during the last quarter. Sivia Capital Partners LLC purchased a new stake in IDEXX Laboratories in the second quarter valued at about $265,000. Jump Financial LLC raised its stake in IDEXX Laboratories by 1,006.4% in the second quarter. Jump Financial LLC now owns 5,532 shares of the company’s stock valued at $2,967,000 after buying an additional 5,032 shares during the last quarter. Cary Street Partners Financial LLC purchased a new stake in IDEXX Laboratories in the second quarter valued at about $164,000. Finally, Sei Investments Co. raised its stake in IDEXX Laboratories by 218.7% in the second quarter. Sei Investments Co. now owns 120,587 shares of the company’s stock valued at $64,678,000 after buying an additional 82,755 shares during the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Trading Down 0.8%

Shares of NASDAQ:IDXX opened at $563.53 on Friday. IDEXX Laboratories, Inc. has a 52-week low of $504.56 and a 52-week high of $769.98. The stock has a market cap of $44.45 billion, a price-to-earnings ratio of 41.50, a PEG ratio of 3.27 and a beta of 1.58. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. The business has a 50-day moving average price of $564.58 and a 200-day moving average price of $637.19.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The firm had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. During the same period last year, the business posted $2.91 earnings per share. The company’s revenue for the quarter was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Equities analysts predict that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on the company. Stifel Nicolaus decreased their price target on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research note on Tuesday, March 31st. BTIG Research reduced their price objective on IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research note on Tuesday, February 3rd. UBS Group reduced their price objective on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research note on Tuesday, April 28th. Wall Street Zen cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Finally, Weiss Ratings cut IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. Seven equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $751.00.

Insiders Place Their Bets

In related news, EVP Nimrata Hunt sold 1,758 shares of IDEXX Laboratories stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $634.57, for a total transaction of $1,115,574.06. Following the completion of the transaction, the executive vice president directly owned 18,141 shares in the company, valued at approximately $11,511,734.37. This trade represents a 8.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.79% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.